A rolling NDA seeking the approval of avutometinib plus defactinib in recurrent KRAS-mutant low-grade serous ovarian cancer has been submitted to the FDA.
FDA approves nivolumab and hyaluronidase-nvhy for subcutaneous injection
Discover the immunobiology of Myelodysplastic syndrome and Aplastic anaemia, the role of CD4+ T cells in myeloid malignancies, and more. Listen today
Key PointsAt 24-, 36-, and 48-month FU, 10% of AYAs with chronic ITP attain yearly SCROT.Higher platelet counts and lower use of rescue therapy during…
During a Case-Based Roundtable® event, Joshua K. Sabari, MD, discussed the mechanism of action of amivantamab and the MARIPOSA trial in patients with EGFR-mutated non–small…
Asciminib continued to improve outcomes when compared to investigator-selected TKIs in patients with newly diagnosed, Ph+ CML-CP in the ASC4FIRST trial.
A calorie deficit occurs when you burn more calories than you consume, says senior clinical dietitian Jessica Tilton. Here, she explains how physical activity and…
Here we present a visual abstract of a retrospective study by Decaux et al. which evaluated real-world outcomes following at least one dose of Isa-Pd…
The antibody-drug conjugate showed a higher objective response rate but failed to meet the primary OS endpoint in patients with pretreated advanced urothelial carcinoma.
Register for Exploring a New Generation of Patient-Centric Cancer Clinical Trials, a virtual patient advocacy event hosted by the AACR.
The Paris System for Reporting Urinary Cytology (TPS) requires at least 5–10 malignant cells to diagnose HGUC in lower and upper urinary tract specimens, respectively,…
